Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression

Adjuvant durvalumab after chemoradiotherapy (CRT) is the standard of care for unresectable stage III non-small cell lung cancer (NSCLC). A post hoc exploratory analysis of PACIFIC revealed no OS benefit in the PD-L1 < 1% subgroup. This retrospective analysis assesses the real-world impact of durv...

Descripción completa

Detalles Bibliográficos
Autores principales: Denault, Marie-Hélène, Feng, Jamie, Kuang, Shelley, Shokoohi, Aria, Leung, Bonnie, Liu, Mitchell, Berthelet, Eric, Laskin, Janessa, Sun, Sophie, Zhang, Tina, Ho, Cheryl, Melosky, Barbara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453050/
https://www.ncbi.nlm.nih.gov/pubmed/37623024
http://dx.doi.org/10.3390/curroncol30080543

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453050/
https://www.ncbi.nlm.nih.gov/pubmed/37623024
http://dx.doi.org/10.3390/curroncol30080543

Ejemplares similares